Neurologist Dr. Leah Croll talks about the new research suggesting they might help in treating people with alcohol use ...

Children who are living with severe obesity are more likely to experience a clinically relevant change in BMI when GLP-1 agonist drugs form part of their treatment, new research being presented at ...

However, it is important to note that the study's cross-sectional design means these findings are correlational, not causal; the data do not show that these factors cause interest in GLP-1 use.

New research has found that GLP-1 drugs can substantially reduce the risk of obesity-related cancers — and they’re more ...

GLP-1 drugs have helped ... on proper medication use, resistance training, and adequate protein intake. Body composition was measured at the start of the study, at three months, and again at ...

Study presented at DDW ... trial design to support drug development. The study titled, "A Genetic Risk Score Associated with Nausea Resulting from GLP-1 Agonist Treatment: A Post-Hoc Analysis ...

The trends worry health experts, who say the medicines have potential to narrow differences in obesity rates among ...

The phase 2 ELAD study of Novo Nordisk's once-daily injectable GLP-1 agonist liraglutide in people with early-stage Alzheimer's has shown that the drug was able to reduce shrinking in the areas of ...

Eli Lilly announced Thursday the successful completion of a phase 3 trial of Orforglipron – the first small-molecule GLP-1 that is administered ... highest dose of the drug scored an A1C less ...

Share on Pinterest Research is looking for ways to minimize muscle loss from GLP-1 drugs taken to treat ... said that “this study was helpful to show that some muscle can occur with significant ...